Soluble receptor for advanced glycation end products (sRAGE) and carotid intima-media thickness (CIMT) in type 1 diabetes Mellitus: Possible association with diabetic vascular complications

Advanced glycation end products (AGEs) are a heterogeneous and complex group of biochemical compounds, resulting from nonenzymatic glycation and oxidation of protein, nucleic acids, and lipids. To assess sRAGE and CIMT in patients with T1DM and their relation to glycemic control and diabetic vascular complications. This study included 60 patients with mean age of 14.4±3.4years. They were subdivided into complicated and non complicated groups according to the presence of microvascular complications. Thirty age and sex matched controls were included. Patients with disease duration less than 5years, connective tissue disease, liver dysfunction, or apparent cardiovascular disease and those on lipid lowering agents were excluded. Laboratory investigations included; HbA1c%, urinary albumin excretion (UAE), fasting lipid profile and sRAGE. Mean CIMT was measured by dopplex ultrasound. Patients had higher sRAGE (1765.0±451.0pg/ml) (p